Skip to content
approvedImmune & Inflammation

Vancomycin

Also known as: Vancocin, Firvanq, Vancomycin HCl

Vancomycin is a glycopeptide antibiotic originally isolated from Amycolatopsis orientalis (formerly Nocardia orientalis) in the 1950s. It is one of the most important antibiotics in clinical medicine, serving as a critical last-line defense against methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant gram-positive infections. Administered intravenously for systemic infections and orally for Clostridioides difficile (C. diff) colitis, vancomycin remains irreplaceable in hospital medicine despite being one of the oldest antibiotics still in frontline use. Its glycopeptide structure — a modified heptapeptide core with sugar moieties — makes it one of the largest clinically used antibiotics.

3 cited references·5 researched benefits

Quick Answer

Vancomycin is a glycopeptide antibiotic and critical last-line treatment for MRSA and other resistant gram-positive infections. Its heptapeptide core binds D-Ala-D-Ala termini of peptidoglycan precursors, blocking bacterial cell wall synthesis. Administered IV for systemic MRSA infections and orally for C. difficile colitis, vancomycin remains essential in hospital medicine. It requires therapeutic drug monitoring (trough levels 15-20 mcg/mL for serious infections) due to nephrotoxicity risk.

Key Facts

Mechanism
Vancomycin inhibits bacterial cell wall synthesis by binding with high affinity to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the lipid II peptidoglycan precursor on the outer surface of the cytoplasmic membrane. This sterically blocks both transglycosylase (preventing polymerization of disaccharide-pentapeptide units) and transpeptidase (preventing cross-linking) enzymes required for peptidoglycan assembly. The result is a weakened cell wall that cannot withstand osmotic pressure, leading to bacterial lysis. The molecule consists of a modified linear heptapeptide backbone with extensive cross-linking, chlorinated aromatic rings, and disaccharide (vancosamine and glucose) moieties. It is too large to penetrate the gram-negative outer membrane, explaining its gram-positive-only spectrum. Vancomycin-resistant organisms (VRE) modify the target to D-Ala-D-Lac, reducing binding affinity 1,000-fold.
Research Status
approved
Half-Life
~4-6 hours (normal renal function)
Molecular Formula
C₆₆H₇₅Cl₂N₉O₂₄
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Essential MRSA treatment — gold-standard therapy for serious MRSA infections including bacteremia, endocarditis, osteomyelitis, and pneumoniastrong
  • Effective against Clostridioides difficile — oral vancomycin is guideline-recommended first-line therapy for C. diff colitisstrong
  • Broad gram-positive coverage — active against virtually all streptococci, most enterococci (except VRE), and all MSSA/MRSAstrong
  • Proven safety profile over 60+ years — one of the longest clinical track records of any antibiotic; well-characterized pharmacokineticsstrong
  • Surgical prophylaxis in MRSA-prevalent settings — standard perioperative prophylaxis for cardiac, orthopedic, and neurosurgical procedures in penicillin-allergic patientsstrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion (systemic MRSA infections)15-20 mg/kg per doseEvery 8-12 hoursWeight-based dosing using actual body weight. Infuse over at least 1-2 hours to avoid red man syndrome. Target AUC/MIC 400-600 (current guideline-recommended approach) or trough 15-20 mcg/mL for serious infections. Loading dose of 25-30 mg/kg may be considered for critically ill patients. Maximum single dose typically 2-3 g.
Oral (Clostridioides difficile colitis)125 mg4 times daily for 10-14 daysOral vancomycin is NOT absorbed systemically — it works locally in the gut lumen against C. diff. Dose may be increased to 500 mg QID for fulminant C. diff. Can also be given as retention enema (500 mg in 100 mL NS) for ileus cases. Fidaxomicin is an alternative with lower recurrence rates.
Intravenous (surgical prophylaxis)15 mg/kg (typically 1-1.5 g)Single dose 1-2 hours before incisionUsed for perioperative prophylaxis in patients with beta-lactam allergy or in settings with high MRSA prevalence. Infusion must begin early enough to complete before surgical incision. Redose at 12 hours for prolonged procedures.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nephrotoxicity — acute kidney injury in 5-25% of patients, dose and duration dependent; higher risk with concurrent nephrotoxinsserious
  • Red man syndrome — histamine-mediated flushing, erythema, and pruritus of the upper body if infused too rapidly; prevented by slow infusion over 1-2 hourscommon
  • Ototoxicity — hearing loss reported, particularly at high trough levels or with concurrent aminoglycosides; largely reversible if caught earlyserious
  • Phlebitis — local venous irritation and pain at IV infusion site; use central line for prolonged coursescommon
  • Thrombocytopenia — immune-mediated platelet destruction in 5-10% of patients, usually after 7+ days of therapyrare
  • Linear IgA bullous dermatosis — rare but characteristic drug eruption with blistering skin lesionsrare

Frequently Asked Questions

What is red man syndrome and how is it prevented?
Red man syndrome (RMS) is a histamine-mediated reaction caused by rapid vancomycin infusion, characterized by flushing, erythema, and itching of the face, neck, and upper torso. It is NOT a true allergy — it results from direct mast cell degranulation by vancomycin. It is prevented by infusing vancomycin slowly, over at least 1-2 hours (no faster than 10 mg/minute). Pretreatment with diphenhydramine can further reduce risk. Patients who experience RMS can safely receive vancomycin again with slower infusion rates.
What is vancomycin-resistant enterococcus (VRE)?
VRE are enterococcal bacteria (usually E. faecium) that have acquired genes (vanA, vanB) modifying the peptidoglycan target from D-Ala-D-Ala to D-Ala-D-Lac, reducing vancomycin binding affinity by approximately 1,000-fold. VRE is a major hospital-acquired pathogen and a CDC "serious threat." Treatment options for VRE include linezolid, daptomycin, and tigecycline. The concern is potential transfer of vancomycin resistance genes from VRE to Staphylococcus aureus, which has occurred rarely (VRSA), creating nearly untreatable infections.
Why does oral vancomycin only work for C. diff and not other infections?
Oral vancomycin is a large glycopeptide molecule (~1,450 daltons) that is essentially not absorbed from the gastrointestinal tract — less than 1% reaches systemic circulation. This makes it useless for treating bloodstream, lung, or tissue infections when given orally. However, for C. diff colitis, this is actually ideal: high concentrations (100-1,000+ mcg/mL) accumulate in the gut lumen where C. diff resides, directly killing the organism without systemic side effects. For any infection outside the GI tract, IV vancomycin is required.
Is vancomycin a peptide?
Yes. Vancomycin is classified as a glycopeptide antibiotic. Its core structure is a modified heptapeptide (7 amino acid) backbone containing unusual amino acids and extensive cross-linking between aromatic side chains. Two sugar moieties (vancosamine and glucose) are attached, making it a "glycopeptide." At approximately 1,450 daltons, it is one of the largest antibiotics in clinical use. Its peptide nature is responsible for both its mechanism of action (binding to D-Ala-D-Ala peptide targets in bacteria) and its pharmacokinetic properties (poor oral absorption, renal clearance).

References

  1. 1
    Vancomycin revisited: a reappraisal of clinical use(2009)PubMed ↗
  2. 2
    Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline(2020)PubMed ↗
  3. 3
    Clinical practice guidelines by IDSA and SHEA for Clostridioides difficile infection in adults: 2021 update(2021)PubMed ↗

Latest Research

Last updated: 2026-02-19